TP53 and B-cell chronic lymphocytic leukemia: The promising therapeutic activity of PEITC against p53-defficient CLL cells in vitro and in vivo suggests that this compound has a potential for use in treatment of CLL patients with 17p-deletion, and warrants further evaluation in clinical setting.